Prediction of longitudinal functional outcomes in schizophrenia: The impact of baseline motivational deficits

Schizophrenia Research

Volumn 132, Issue 1, 2011, Pages 24-27

  Foussias, G ^a,b   Mann, S ^a,b   Zakzanis, K K ^a   van Reekum, R ^b   Agid, O ^a   Remington, G ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

Apathy; Cognition; Functioning; Motivation; Negative symptoms; Pleasure; Schizophrenia

Indexed keywords

ADULT; ARTICLE; CALGARY DEPRESSION SCALE FOR SCHIZOPHRENIA; CLINICAL ARTICLE; DEPRESSION; FEMALE; FOLLOW UP; FUNCTIONAL STATUS; HUMAN; LONGITUDINAL STUDY; MALE; MOTIVATION; MOTIVATIONAL DEFICIT; NEGATIVE SYNDROME; POSITIVE SYNDROME; PREDICTION; PRIORITY JOURNAL; PSYCHOLOGICAL RATING SCALE; QUALITY OF LIFE; SCALE FOR THE ASSESSMENT OF POSITIVE SYMPTOMS; SCHIZOPHRENIA;

ADOLESCENT; ADULT; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; MOOD DISORDERS; MOTIVATION; PREDICTIVE VALUE OF TESTS; PSYCHIATRIC STATUS RATING SCALES; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; YOUNG ADULT;

EID: 80052633733     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2011.06.026     Document Type: Article

References (36)

1. Addington D., Addington J., Schissel B. A depression rating scale for schizophrenics. Schizophr. Res. 1990, 3(4):247-251.
2. Andreasen N.C. Negative symptoms in schizophrenia. Definition and reliability. Arch. Gen. Psychiatry 1982, 39(7):784-788.
3. Andreasen N.C. Scale for the Assessment of Positive Symptoms (SAPS) 1984, University of Iowa, Iowa City, IA.
4. Andreasen N.C., Pressler M., Nopoulos P., Miller D., Ho B.C. Antipsychotic dose equivalents and dose-years: a standardized method for comparing exposure to different drugs. Biol. Psychiatry 2010, 67(3):255-262.
5. Barnes T.R. A rating scale for drug-induced akathisia. Br. J. Psychiatry 1989, 154:672-676.
6. Blanchard J.J., Horan W.P., Collins L.M. Examining the latent structure of negative symptoms: is there a distinct subtype of negative symptom schizophrenia?. Schizophr. Res. 2005, 77(2-3):151-165.
7. Bleuler E. Dementia Praecox or the Group of Schizophrenias 1950, International Universities Press, New York, (548 pp.).
8. Faerden A., Friis S., Agartz I., Barrett E.A., Nesvag R., Finset A., Melle I. Apathy and functioning in first-episode psychosis. Psychiatr. Serv. 2009, 60(11):1495-1503.
9. Faerden A., Finset A., Friis S., Agartz I., Barrett E.A., Nesvag R., Andreassen O.A., Marder S.R., Melle I. Apathy in first episode psychosis patients: one year follow up. Schizophr. Res. 2010, 116(1):20-26.
10. Foussias G., Remington G. Negative symptoms in schizophrenia: avolition and Occam's razor. Schizophr. Bull. 2010, 36(2):359-369.
11. Foussias G., Mann S., Zakzanis K.K., van Reekum R., Remington G. Motivational deficits as the central link to functioning in schizophrenia: a pilot study. Schizophr. Res. 2009, 115(2-3):333-337.
12. Gard D.E., Gard M.G., Kring A.M., John O.P. Anticipatory and consummatory components of the experience of pleasure: a scale development study. J. Res. Pers. 2006, 40:1086-1102.
13. Gard D.E., Kring A.M., Gard M.G., Horan W.P., Green M.F. Anhedonia in schizophrenia: distinctions between anticipatory and consummatory pleasure. Schizophr. Res. 2007, 93(1-3):253-260.
14. Green M.F., Kern R.S., Heaton R.K. Longitudinal studies of cognition and functional outcome in schizophrenia: implications for MATRICS. Schizophr. Res. 2004, 72(1):41-51.
15. Gur R.E., Kohler C.G., Ragland J.D., Siegel S.J., Lesko K., Bilker W.B., Gur R.C. Flat affect in schizophrenia: relation to emotion processing and neurocognitive measures. Schizophr. Bull. 2006, 32(2):279-287.
16. Heinrichs R.W., Zakzanis K.K. Neurocognitive deficit in schizophrenia: a quantitative review of the evidence. Neuropsychology 1998, 12(3):426-445.
17. Heinrichs D.W., Hanlon T.E., Carpenter W.T. The quality of life scale: an instrument for rating the schizophrenic deficit syndrome. Schizophr. Bull. 1984, 10(3):388-398.
18. Ho B.C., Nopoulos P., Flaum M., Arndt S., Andreasen N.C. Two-year outcome in first-episode schizophrenia: predictive value of symptoms for quality of life. Am. J. Psychiatry 1998, 155(9):1196-1201.
19. Jones P.B., Barnes T.R., Davies L., Dunn G., Lloyd H., Hayhurst K.P., Murray R.M., Markwick A., Lewis S.W. Randomized controlled trial of the effect on quality of life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Arch. Gen. Psychiatry 2006, 63(10):1079-1087.
20. Kane J.M., Aguglia E., Altamura A.C., Ayuso Gutierrez J.L., Brunello N., Fleischhacker W.W., Gaebel W., Gerlach J., Guelfi J.D., Kissling W., et al. Guidelines for depot antipsychotic treatment in schizophrenia. European Neuropsychopharmacology Consensus Conference in Siena, Italy. Eur. Neuropsychopharmacol. 1998, 8(1):55-66.
21. Keefe R.S., Goldberg T.E., Harvey P.D., Gold J.M., Poe M.P., Coughenour L. The Brief Assessment of Cognition in Schizophrenia: reliability, sensitivity, and comparison with a standard neurocognitive battery. Schizophr. Res. 2004, 68(2-3):283-297.
22. Kelley M.E., van Kammen D.P., Allen D.N. Empirical validation of primary negative symptoms: independence from effects of medication and psychosis. Am. J. Psychiatry 1999, 156(3):406-411.
23. Kiang M., Christensen B.K., Remington G., Kapur S. Apathy in schizophrenia: clinical correlates and association with functional outcome. Schizophr. Res. 2003, 63(1-2):79-88.
24. Kimhy D., Yale S., Goetz R.R., McFarr L.M., Malaspina D. The factorial structure of the schedule for the deficit syndrome in schizophrenia. Schizophr. Bull. 2006, 32(2):274-278.
25. Kirkpatrick B., Fenton W.S., Carpenter W.T., Marder S.R. The NIMH-MATRICS consensus statement on negative symptoms. Schizophr. Bull. 2006, 32(2):214-219.
26. Kraepelin E. Dementia Praecox and Paraphrenia 1919, Livingstone, Edinburgh, (x, 331 pp.).
27. Lieberman J.A., Stroup T.S., McEvoy J.P., Swartz M.S., Rosenheck R.A., Perkins D.O., Keefe R.S., Davis S.M., Davis C.E., Lebowitz B.D., et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N. Engl. J. Med. 2005, 353(12):1209-1223.
28. Marin R.S., Biedrzycki R.C., Firinciogullari S. Reliability and validity of the apathy evaluation scale. Psychiatry Res. 1991, 38(2):143-162.
29. Milev P., Ho B.C., Arndt S., Andreasen N.C. Predictive values of neurocognition and negative symptoms on functional outcome in schizophrenia: a longitudinal first-episode study with 7-year follow-up. Am. J. Psychiatry 2005, 162(3):495-506.
30. Mueser K.T., Sayers S.L., Schooler N.R., Mance R.M., Haas G.L. A multisite investigation of the reliability of the Scale for the Assessment of Negative Symptoms. Am. J. Psychiatry 1994, 151(10):1453-1462.
31. Nakagami E., Xie B., Hoe M., Brekke J.S. Intrinsic motivation, neurocognition and psychosocial functioning in schizophrenia: testing mediator and moderator effects. Schizophr. Res. 2008, 105(1-3):95-104.
32. Peralta V., Cuesta M.J. Dimensional structure of psychotic symptoms: an item-level analysis of SAPS and SANS symptoms in psychotic disorders. Schizophr. Res. 1999, 38(1):13-26.
33. Rosenheck R., Leslie D., Keefe R., McEvoy J., Swartz M., Perkins D., Stroup S., Hsiao J.K., Lieberman J. Barriers to employment for people with schizophrenia. Am. J. Psychiatry 2006, 163(3):411-417.
34. Sayers S.L., Curran P.J., Mueser K.T. Factor structure and construct validity of the scale for the assessment of negative symptoms. Psychol. Assess. 1996, 8(3):269-280.
35. Sheehan D.V., Lecrubier Y., Sheehan K.H., Amorim P., Janavs J., Weiller E., Hergueta T., Baker R., Dunbar G.C. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J. Clin. Psychiatry 1998, 59(Suppl. 20):22-33.
36. Simpson G.M., Angus J.W. A rating scale for extrapyramidal side effects. Acta Psychiatr. Scand. Suppl. 1970, 212:11-19.